**STUDY DESIGN**

**Patient cohorts**

<table>
<thead>
<tr>
<th>SARA 11/18 comparator</th>
<th>Real World Comparator</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total number of patients</td>
<td>16</td>
</tr>
<tr>
<td>Total number of patients</td>
<td>16</td>
</tr>
<tr>
<td>Total number of patients</td>
<td>124</td>
</tr>
</tbody>
</table>

The primary objective of the study is to evaluate the benefits and risks of an anticancer therapy against the comparator therapy in patients with advanced NSCLC. The primary endpoint of the study is overall survival (OS) and progression-free survival (PFS).

**Primary Objectives**

- **Overall Survival (OS)**
- **Progression-Free Survival (PFS)**

A pair-matched patient can have more than one eligible line of therapy for maximizing the UK criteria at the start of each phase III trial.

The cohorts were balanced to improve their comparability.

**Overall Survival (OS) & OS at 26 weeks**

87.1% vs 60.2%

**Balanced cohorts**

- **Overall Survival (OS)**
- **Progression-Free Survival (PFS)**

**Time to Subsequent Therapy (TTS)**

**Progression-Free Survival (PFS)**

**CONCLUSIONS**

- **MVX-ONCO is a novel personalized cancer vaccine using Encapsulating Cell Technology, currently in Phase IIa.**
- **MVX-ONCO is very safe with no systemic therapy related adverse event reported in >50 treated patients.**
- **Early analysis on all 16 heavily pretreated R/M HNSCC pts is intriguing with clear signs of immune stimulation, tumor control and prolonged survival.**
- **This Real-World Comparator Study was conducted to have a better understanding of the potential therapeutic effect of MVX-ONCO on survival in pts with advanced R/M HNSCC, in progression after at least one prior line of systemic anticancer therapy.**
- **These results clearly show a meaningful improvement in Median OS and an ARR of death of 26.9% at 26 weeks and 34.0% at 12 months.**
- **The subgroup analysis of pts receiving subsequent therapies is also favorable to MVX-ONCO.**
- **With strong signs of single agent activity, very good safety profile and biological evidence of synergy between cell-based vaccine and IO, combination therapy with anti-PD-1/PD-L1 mAbs should be tested in R/M HNSCC and other cancers such as NSCLC, melanoma, kidney, bladder, and liver.